Janux Therapeutics (NASDAQ:JANX – Get Free Report) and Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.
Insider and Institutional Ownership
75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings for Janux Therapeutics and Nektar Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Janux Therapeutics | 2 | 2 | 10 | 1 | 2.67 |
| Nektar Therapeutics | 1 | 2 | 9 | 1 | 2.77 |
Risk and Volatility
Janux Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
Profitability
This table compares Janux Therapeutics and Nektar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Janux Therapeutics | N/A | -11.89% | -11.13% |
| Nektar Therapeutics | -287.84% | -37.87% | -25.67% |
Valuation & Earnings
This table compares Janux Therapeutics and Nektar Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Janux Therapeutics | $10.00 million | 114.58 | -$113.62 million | ($1.64) | -11.43 |
| Nektar Therapeutics | $55.23 million | 44.99 | -$164.08 million | ($6.70) | -10.86 |
Janux Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Janux Therapeutics beats Nektar Therapeutics on 10 of the 14 factors compared between the two stocks.
About Janux Therapeutics
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
